Original research
by
Boilard, Philippe et al
Release Date
2024
Geography
Canada
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
This study describes rates of injectable Injectable extended-release buprenorphine (BUP-ER) (Sublocade®) uptake in five provinces to compare access to this novel medication across Canada.
Findings/Key points
In total, 6528 individuals were treated with injectable BUP-ER, with the majority in British Columbia (29.0 %) and Ontario (47.0 %). By March 2022, the rate of BUP-ER use was highest in British Columbia (16.6 per 100,000), and lowest in Ontario (9.1 per 100,000). The rate of BUP-ER use was higher in rural areas (15.5 per 100,000) compared to urban centres (10.6 per 100,000), and British Columbia had the highest rate of prescribers per 100,000 population (5.9) compared to Ontario (2.2), Alberta (2.3), Saskatchewan (3.4) and Manitoba (3.5) by the end of Q1–2022.
There is also an infographic available about this study.
Design/methods
We conducted a retrospective time-series analysis among individuals who received injectable BUP-ER in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario from February 1, 2020, to March 31, 2022.
Keywords
Barriers and enablers
Equity
Rural/remote
Substitution/OAT
